| Chairman |
|
Kang Xiaoqiang |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman, Chief Executive Officer & General Manager: Kang Xiaoqiang
Executive Director: Lai Shoupeng, Zuo Honggang
Non-executive Director: Zhang Yincheng, Chen Renhai
Independent Non-executive Director: Zhang Hongbing, Du Yilong, Du Jiliu.
|
| Principle Business |
|
The Group is principally engaged in biopharmaceutical business, focusing on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. |
| Related Indexes | | Hang Seng Healthcare Industry Index | Hang Seng Composite Index | | Hang Seng Healthcare Index | Hang Seng Composite SmallCap Index |
|
| Major Shareholders |
| Lin Lijun | 12,674,142 | NON-H SHS | 6.55% | 27.79% | 2025/07/25 | | Kang Xiaoqiang | 12,520,032 | H Sh | 6.47% | 8.47% | 2025/07/25 | | Kang Xiaoqiang | 11,783,967 | NON-H SHS | 6.09% | 25.83% | 2025/07/25 | | Yuan Quanhong | 10,889,631 | H Sh | 5.63% | 7.37% | 2025/07/25 | | Nanjing Jiangbei New Area Management Committee | 9,318,524 | H Sh | 4.82% | 6.31% | 2025/07/25 | | Chen Renhai | 8,118,024 | H Sh | 4.20% | 5.49% | 2025/07/25 | | Chen Renhai | 6,765,170 | NON-H SHS | 3.50% | 14.83% | 2025/07/25 | | Nanjing Jiangbei New Area Management Committee | 3,432,418 | NON-H SHS | 1.78% | 7.53% | 2025/07/25 | | Yuan Quanhong | 1,683,194 | NON-H SHS | 0.87% | 3.69% | 2025/07/25 | | Lin Lijun | 895,954 | H Sh | 0.46% | 0.61% | 2025/07/25 |
|
|
|
|
|